AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have been assigned a consensus rating of “Moderate Buy” from the eleven analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $73.4444.

Several research analysts have recently weighed in on the company. HC Wainwright boosted their target price on AnaptysBio from $51.00 to $66.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Wedbush reaffirmed an “outperform” rating and issued a $50.00 price target on shares of AnaptysBio in a report on Monday, November 24th. Truist Financial lifted their price objective on AnaptysBio from $36.00 to $50.00 and gave the stock a “hold” rating in a research report on Friday, March 6th. Guggenheim reissued a “buy” rating on shares of AnaptysBio in a research note on Thursday, December 18th. Finally, Barclays raised their target price on AnaptysBio from $78.00 to $79.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 4th.

Insider Transactions at AnaptysBio

In other AnaptysBio news, insider Eric J. Loumeau sold 10,000 shares of the business’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $54.00, for a total value of $540,000.00. Following the transaction, the insider directly owned 12,835 shares in the company, valued at $693,090. The trade was a 43.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Magda Marquet sold 11,000 shares of the stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $48.23, for a total transaction of $530,530.00. Following the completion of the sale, the director directly owned 9,930 shares of the company’s stock, valued at approximately $478,923.90. This trade represents a 52.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 156,280 shares of company stock valued at $7,254,939 in the last three months. 33.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC increased its stake in AnaptysBio by 5,864.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 821 shares during the last quarter. Larson Financial Group LLC increased its position in shares of AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 473 shares during the last quarter. Bessemer Group Inc. raised its holdings in AnaptysBio by 950.0% in the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 1,292 shares during the period. Tower Research Capital LLC TRC lifted its position in AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,377 shares during the last quarter. Finally, Osaic Holdings Inc. boosted its stake in AnaptysBio by 11,630.0% during the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after buying an additional 2,326 shares during the period.

AnaptysBio Trading Up 4.3%

NASDAQ:ANAB opened at $64.67 on Friday. The company’s 50-day moving average price is $51.05 and its 200-day moving average price is $40.04. The company has a market cap of $1.86 billion, a P/E ratio of -124.36 and a beta of 0.32. AnaptysBio has a twelve month low of $15.32 and a twelve month high of $66.66.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, March 3rd. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.69. The company had revenue of $108.25 million during the quarter, compared to analysts’ expectations of $87.09 million. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%. On average, analysts expect that AnaptysBio will post -6.08 earnings per share for the current year.

AnaptysBio declared that its Board of Directors has authorized a stock repurchase plan on Friday, November 21st that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the biotechnology company to buy up to 9.6% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s management believes its stock is undervalued.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.